Enanta is a clinical stage biotechnology company dedicated to creating oral drugs for viral infections. Our story began in 1995 when we grew from humble beginnings to the company we are today — one that collaborated with AbbVie to discover two protease inhibitor compounds that were each developed and commercialized as part of an AbbVie combination regimen for chronic hepatitis C virus (MAVYRET® and VIEKIRA PAK®, respectively). Currently, we have a diverse and robust pipeline, including one of the most advanced respiratory virology treatment portfolios in the industry, which we are progressing through clinical development with programs for respiratory syncytial virus, SARS-CoV-2 and human metapneumovirus. We are also advancing a clinical stage program for a combination treatment for chronic hepatitis B virus infection.
From our CEO
Enanta Pharmaceuticals is driven to develop best-in-class oral therapies that profoundly improve patients’ lives. We are focused on discovering novel drugs by leveraging proven methods grounded in medicinal chemistry, molecular virology and pharmacology. Through scientific excellence and imagination, we leverage our expertise in small molecule drugs to discover and develop groundbreaking medicines. Our vision is clear: we aim to transform the lives of patients with curative therapies.
Our previous success includes the discovery and development of two protease inhibitor compounds through our collaboration with AbbVie, which are sold as part of AbbVie’s combination regimens for chronic hepatitis C virus. These two regimens, which are marketed under the trade names VIEKIRA PAK® and MAVYRET®, have helped cure hundreds of thousands of patients. We now work in multiple disease areas and are developing a leading treatment portfolio for viral respiratory infections, with programs for respiratory syncytial virus, COVID-19 and human metapneumovirus. We also are building on our liver virology expertise with our program for a combination treatment for chronic hepatitis b virus infection.
At Enanta, we are proving that dedication can make a meaningful difference for patients suffering from serious respiratory infections and liver diseases.
Jay R. Luly, Ph.D.
President, Chief Executive Officer and Director